Shnayder S

Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.

6 papers · 2 preprints

ArticlePsilocybin

Mystical but not challenging experiences predict symptom improvement after psilocybin for treatment-resistant OCD.

Shnayder S, Agin-Liebes G, Hubert TJ +5

Europe PMC2026
ArticlePsilocybin

Surrender, disidentification, and reappraisal: a qualitative comparison of psilocybin responders and non-responders in treatment-resistant OCD.

Agin-Liebes G, Shnayder S, Fram G +6

Europe PMC2026
PreprintPsilocybin

Mystical but Not Challenging Experiences Predict Symptom Improvement After Psilocybin for Treatment-Resistant OCD

Shnayder S, Agin-Liebes G, Hubert T +5

Europe PMC2026
PreprintPsilocybin

Psilocybin for Treatment-Resistant OCD: A Randomized Controlled Trial

Kelmendi B, Adams T, Ching THW +16

Europe PMC2026
ArticlePsilocybin

Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis.

Ching THW, Stahnke B, Shnayder S +22

Europe PMC2025
ArticlePsilocybin

Corrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings.

Ching THW, Amoroso L, Bohner C +16

Europe PMC2024
ArticlePsilocybin

Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings.

Ching THW, Amoroso L, Bohner C +15

Europe PMC2023
ArticlePsilocybin

Psilocybin-assisted therapy improves psycho-social-spiritual well-being in cancer patients.

Shnayder S, Ameli R, Sinaii N +2

Europe PMC2023